Work

8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)

Year: 2026
Type: article
Abstract: The Advanced Breast Cancer (ABC) 8th international consensus conference took place on 6-8 November 2025, in Lisbon, and updated the previous ABC international consensus guidelines that are described in this manuscript. These guidelines reflect the work of a large and global consensus panel, comprising healthcare professionals and patients, and provide recommendations on how to best manage patients with advanced breast cancer (inoperable locally advanced or metastatic), of all breast cancer subtypes. The guidelines are based on the best available evidence or on expert opinion when a higher level of evidence is lacking and aim to cover the needs of the person living with ABC, including but also beyond the main therapeutic recommendations. Each guideline is accompanied by the level of evidence (LoE), the grade of recommendation (GoR), and the percentage of consensus reached at the consensus session. Updated diagnostic and treatment algorithms are also provided. These guidelines are endorsed by several international oncology organizations (AGO, AORTIC, ECO, EONS, ESO, ESTRO, EUSOMA, GECO Perú, SUMA, MASCC, French Breast Cancer Guidelines and AMAAC) and have official representation from ASCO, NCCN and ABC-NZ. Inequalities in access to high-quality care have increased in the last decade, both between and within countries, and are a major concern. The ABC guidelines provide guidance on the best available management options for patients living with ABC globally, assuming availability of the recommended therapies. Their adaptation is often needed in resource-constrained settings, and the grading of each recommendation may help in prioritizing access to available options.
Source: The Breast
Institutions: Centre Antoine Lacassagne, Institut Gustave Roussy, Georgetown University, Georgetown University Medical Center, MedStar Georgetown University Hospital, Hebrew University of Jerusalem, Hadassah Medical Center, Inserm, Université Clermont Auvergne, Centre Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Dana-Farber Cancer Institute, Peter MacCallum Cancer Centre, Waikato District Health Board, University Medical Center Utrecht, Fundación Instituto Valenciano de Oncología, Clinique de Genolier, Tata Memorial Hospital, Eastern Cooperative Oncology Group, Hospital São Lucas da PUCRS, Azienda Usl Toscana Centro, Hospital of Prato, Royal North Shore Hospital, Instituto de Oncología de Rosario, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, National Cancer Centre Singapore, Trinity College Dublin, American University of Beirut Medical Center, Brighton and Sussex Medical School, University of Sussex, Instituto Nacional de Cancerología, Foundation for Clinical and Applied Cancer Research, BC Cancer Agency, Macquarie University, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Tenon, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Ludwig-Maximilians-Universität München, Fudan University Shanghai Cancer Center, Sheba Medical Center, National Health and Medical Research Council, Asan Medical Center, University of Ulsan, Muhimbili National Hospital, Yale Cancer Center, University Medical Center Hamburg-Eppendorf, Aga Khan University Nairobi, Instituto Nacional de Enfermedades Neoplásicas, Sagara Hospital, City of Hope, Europa Donna, University of Hong Kong, Centre Hospitalier Universitaire Brugmann, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Memorial Sloan Kettering Cancer Center, Yale University
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $3,200
OpenAlex ID: W7213464691
FWCI:
Cites: 95
Cited by:
Related to: